

# Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US04/034501

International filing date: 20 October 2004 (20.10.2004)

Document type: Certified copy of priority document

Document details: Country/Office: US

Number: 60/560,754

Filing date: 31 October 2003 (31.10.2003)

Date of receipt at the International Bureau: 06 December 2004 (06.12.2004)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

1253568

UNITED STATES OF AMERICA

TO WHOM THESE PAPERS SHALL COME

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

November 26, 2004

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM  
THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK  
OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT  
APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A  
FILING DATE.

APPLICATION NUMBER: 60/560,754

FILING DATE: *October 31, 2003*

RELATED PCT APPLICATION NUMBER: PCT/US04/34501

Certified by



Jon W Dudas

Acting Under Secretary of Commerce  
for Intellectual Property  
and Acting Director of the U.S.  
Patent and Trademark Office

16179  
103103  
U.S. PTO

Atty. Dkt. No. 085747-0304

03945 U.S.PTO  
10/698011  
103103

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Peter BACH et al.  
Title: NOVEL COMPOUNDS III  
Appl. No.: Unknown  
Filing Date: October 31, 2003  
Examiner: Unknown  
Art Unit: Unknown

**UTILITY PATENT APPLICATION**  
**TRANSMITTAL**

Mail Stop PATENT APPLICATION  
Commissioner for Patents  
PO Box 1450  
Alexandria, Virginia 22313-1450

Sir:

Transmitted herewith for filing under 37 C.F.R. § 1.53(b) is the nonprovisional utility patent application of:

Peter BACH  
Udo BAUER  
Karolina NILSSON  
Andreas WALLBERG

Applicant claims small entity status under 37 CFR 1.27.

Enclosed are:

Specification, Claim(s), and Abstract (23 pages).  
 Assignment of the invention to AstraZeneca and NPS Pharmaceuticals, Inc..  
 Assignment Recordation Cover Sheet.  
 Application Data Sheet (37 CFR 1.76).

The filing fee is calculated below:

	Claims as Filed	Included in Basic Fee	Extra Claims	Rate	Fee Totals
Basic Fee				\$770.00	\$770.00
Total	15	- 20	= 0	\$18.00	\$0.00
Claims:					
Independents:	5	- 3	= 2	\$86.00	\$172.00
If any Multiple Dependent Claim(s) present:			+ 1	\$290.00	\$290.00
Surcharge under 37 CFR 1.16(e) for late filing of Executed Declaration and late payment of filing fee			+ 1	\$130.00	\$130.00
				SUBTOTAL:	\$1362.00
[ ]				Small Entity Fees Apply (subtract 1/2 of above):	\$0.00
				TOTAL FILING FEE:	<u>\$1,362.00</u>

[ ] A check in the amount of \$0.00 to cover the filing fee is enclosed.

[ X ] The required filing fees are not enclosed but will be submitted in response to the Notice to File Missing Parts of Application.

[ ] The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Please direct all correspondence to the undersigned attorney or agent at the address indicated below.

Respectfully submitted,  
*Michael Martin*  
By Reg. No. 34,717

Date Oct 31, 2003  
FOLEY & LARDNER  
Customer Number: 22428  
Telephone: (202) 672-5404  
Facsimile: (202) 672-5399

*for* Stephen A. Bent  
Attorney for Applicant  
Registration No. 29,768

## NOVEL COMPOUNDS III

Field of the invention

5 The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds.

Background of the invention

10 The metabotropic glutamate receptors (mGluR) are G-protein coupled receptors that are involved in the regulation and activity of many synapses in the central nervous system (CNS). Eight metabotropic glutamate receptor subtypes have been identified and are subdivided into three groups based on sequence similarity. Group I consists of mGluR1 and mGluR5. These receptors activate phospholipase C and increase neuronal excitability. 15 Group II, consisting of mGluR2 and mGluR3 as well as group III, consisting of mGluR4, mGluR6, mGluR7 and mGluR8 are capable of inhibiting adenylyl cyclase activity and reduce synaptic transmission. Several of the receptors also exist in various isoforms, occurring by alternative splicing (*Chen, C-Y et al., Journal of Physiology* (2002), 538.3, 20 *pp. 773-786; Pin, J-P et al., European Journal of Pharmacology* (1999), 375, *pp. 277-294; Bräuner-Osborne, H et al. Journal of Medicinal Chemistry* (2000), 43, *pp. 2609-2645; Schoepp, D.D, Jane D.E. Monn J.A. Neuropharmacology* (1999), 38, *pp. 1431-1476*).

25 The lower esophageal sphincter (LES) is prone to relaxing intermittently. As a consequence, fluid from the stomach can pass into the esophagus since the mechanical barrier is temporarily lost at such times, an event hereinafter referred to as "reflux".

30 Gastro-esophageal reflux disease (GERD) is the most prevalent upper gastrointestinal tract disease. Current pharmacotherapy aims at reducing gastric acid secretion, or at neutralizing acid in the esophagus. The major mechanism behind reflux has been considered to depend on a hypotonic lower esophageal sphincter. However, e.g. *Holloway & Dent* (1990)


*Gastroenterol. Clin. N. Amer.* 19, pp. 517-535, has shown that most reflux episodes occur during transient lower esophageal sphincter relaxations (TLESRs), i.e. relaxations not triggered by swallows. It has also been shown that gastric acid secretion usually is normal in patients with GERD.

5

The problem underlying the present invention was to find new compounds useful in the treatment of GERD.

WO 01/16121 A1 discloses a compound A-L-B, where


10 A is a 5-, 6- or 7-membered heterocycle



L is an alkenylene, alkynylene or azo; and

15 B is a hydrocarbyl; cyclohydrocarbyl; heterocycle (optionally containing one or more double bonds); or aryl. These compounds have been described as being useful in inter alia cerebral ischemia, chronic neurodegeneration, psychiatric disorders, epilepsy and diseases of the pulmonary system as well as the cardiovascular system.

WO 99/02497 A2 discloses compounds of the formula



20


wherein X may be an alkenylene or an alkynylene bonded via vicinal unsaturated carbon atoms, or an azo group; and R may be an aromatic or heteroaromatic group. These compounds have been described as being useful in inter alia epilepsy, cerebral ischemia and Alzheimer's disease.

25

Outline of the invention

The present invention is directed to novel compounds according to the general formula I:

5



wherein

- R<sup>1</sup> is selected from hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, aryl and heteroaryl, wherein the aryl or heteroaryl may be substituted by C<sub>1</sub>-C<sub>4</sub> alkyl;
- 10 R<sup>2</sup> is selected from hydrogen and C<sub>1</sub>-C<sub>4</sub> alkyl;
- R<sup>3</sup> is selected from hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, F, CF<sub>3</sub>, CHF<sub>2</sub> and CH<sub>2</sub>F;
- R<sup>4</sup> is selected from hydrogen, F, CF<sub>3</sub>, CHF<sub>2</sub>, CH<sub>2</sub>F and CH<sub>3</sub>;
- R<sup>5</sup> is selected from hydrogen and F;
- 15 R<sup>6</sup> is selected from hydrogen and F;
- Y<sup>1</sup> is selected from hydrogen, halogen, nitrile, C<sub>1</sub>-C<sub>4</sub> alkoxy, and C<sub>1</sub>-C<sub>4</sub> alkyl;
- Y<sup>2</sup> is selected from hydrogen, halogen, nitrile, C<sub>1</sub>-C<sub>4</sub> alkoxy, and C<sub>1</sub>-C<sub>4</sub> alkyl;
- Y<sup>3</sup> is selected from hydrogen, halogen, nitrile, C<sub>1</sub>-C<sub>4</sub> alkoxy, and C<sub>1</sub>-C<sub>4</sub> alkyl;  
with the proviso that when Y<sup>1</sup> is hydrogen, Y<sup>2</sup> is selected from halogen, nitrile, C<sub>1</sub>-C<sub>4</sub> alkoxy, and C<sub>1</sub>-C<sub>4</sub> alkyl;
- 20 as well as pharmaceutically acceptable salts, hydrates, isoforms and/or optical isomers thereof.

The general terms used in the definition of formula I have the following meanings:

Halogen is chloro, fluoro, bromo or iodo.

$C_1-C_4$  alkyl is a straight or branched alkyl group, each independently containing 1, 2, 3 or 4 carbon atoms, for example methyl, ethyl, n-propyl, n-butyl or isopropyl. In one embodiment, the alkyl groups may contain one or more heteroatoms selected from O, N and S. Examples of such groups are methyl-ethylether, methyl-ethylamine and methyl-thiomethyl.

$C_1-C_4$  cycloalkyl is a cyclic alkyl, each independently containing 3, 4, 5 or 6 carbon atoms such as cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.

$C_1-C_4$  alkoxy is an alkoxy group containing 1, 2, 3 or 4 carbon atoms, such as methoxy, ethoxy, n-propoxy, n-butoxy or isopropoxy.

15 The herein used term aryl means aromatic rings with 6-14 carbon atoms including both single rings and polycyclic compounds, such as phenyl, benzyl or naphtyl.

20 The term heteroaryl as used herein means aromatic rings with 5-14 carbon atoms, including both single rings and polycyclic compounds, such as imidazopyridine, in which one or several of the ring atoms is either oxygen, nitrogen or sulphur, such as furanyl or thiophenyl.

25 Within the scope of the invention are also pharmaceutically acceptable salts of the compounds of formula I as well as isomers, hydrates and isoforms thereof.

Pharmaceutically acceptable salts of the compound of formula I are also within the scope of the present invention. Such salts are for example salts formed with mineral acids such as hydrochloric acid; alkali metal salts such as sodium or potassium salts; or alkaline earth metal salts such as calcium or magnesium salts.

The novel compounds according to the present invention are useful in therapy. In one aspect of the invention said compounds are useful for the inhibition of transient lower esophageal sphincter relaxations (TLESRs) and thus for treatment or prevention of gastro-esophageal reflux disorder (GERD). In further embodiments, the compounds according to 5 the present invention are useful for the prevention of reflux, treatment or prevention of regurgitation, treatment or prevention of asthma, treatment or prevention of laryngitis, treatment or prevention of lung disease and for the management of failure to thrive.

A further aspect of the invention is the use of a compound according to formula I, for the 10 manufacture of a medicament for the inhibition of transient lower esophageal sphincter relaxations, for the treatment or prevention of GERD, for the prevention of reflux, for the treatment or prevention of regurgitation, treatment or prevention of asthma, treatment or prevention of laryngitis, treatment or prevention of lung disease and for the management of failure to thrive.

15 Still a further aspect of the invention is a method for the treatment of any one of the conditions mentioned above, whereby a pharmaceutically effective amount of a compound according to formula I above, is administered to a subject suffering from said condition(s).

20 In one aspect of the invention, the compounds of formula I are useful for the treatment and/or prevention of acute and chronic neurological and psychiatric disorders, anxiety and chronic and acute pain disorders. In a further aspect, said compounds are useful for the prevention and/or treatment of pain related to migraine, inflammatory pain, neuropathic pain disorders such as diabetic neuropathies, arthritis and rheumatoid diseases, low back 25 pain, post-operative pain and pain associated with various conditions including cancer, angina, renal or biliary colic, menstruation, migraine and gout.

The term "isomers" is herein defined as compounds of formula I, which differ by the 30 position of their functional groups and/or orientation. By "orientation" is meant stereoisomers, diastereoisomers, regioisomers and enantiomers.


The term "isoforms" as used herein is defined as compounds of formula I which differ by their crystal lattice, such as crystalline compounds and amorphous compounds.

- 5 The wording "TLESR", transient lower esophageal sphincter relaxations, is herein defined in accordance with *Mittal, R.K., Holloway, R.H., Penagini, R., Blackshaw, L.A., Dent, J., 1995; Transient lower esophageal sphincter relaxation. Gastroenterology 109, pp. 601-610.*
- 10 The wording "reflux" is defined herein as fluid from the stomach being able to pass into the esophagus, since the mechanical barrier is temporarily lost at such times.

The wording "GERD", gastro-esophageal reflux disease, is defined herein in accordance with *van Heerwarden, M.A., Smout A.J.P.M., 2000; Diagnosis of reflux disease. Baillière's Clin. Gastroenterol. 14, pp. 759-774.*


#### Methods of preparation

- 20 First, a Sonogashira coupling (*Tetrahedron Letters* 1975, 50, 4467, S. Thorand, N. Krause *J. Org. Chem.*, 1998, 63, 8551-8553, M. Erdélyi, A. Gogoll, *J. Org. Chem.*, 2001, 66, 4165-4169) of the aryl bromide A and the alcohol B in the presence of a base such as triethyl amine at room temperature to 60 °C gives the alcohol C which is then converted into the mesylate D with methanesulfonyl chloride in triethyl amine at about 0 to -20 °C.
- 25 The mesylate of the primary alcohol is isolated and characterised, while that of the secondary alcohols are made in situ. Finally, the respective mesylate is reacted with the alcohol. This can either be done by adding the alcohol and a base such as triethyl amine to the mesylate in a solvent such as DCM or by pre-reacting the alcohol with a base such as sodium hydride in a solvent such as THF and subsequently adding the mesylate to this
- 30 solution to generate product (I) (Scheme 1).




SCHEME 1

In those cases where the alcohol B is not commercially available with a desired R<sup>1</sup>-group, 5 the product (I) is formed by an alternative route (scheme 2): first the aryl bromide A is coupled with ethynyl(trimethyl)silane F via Sonogashira coupling at 60 °C in triethyl amine to give product G. Deprotection of G at room temperature with potassium carbonate in methanol/DCM gives terminal alkyne H, which is deprotonated with lithium 10 bis(trimethylsilyl)amide in THF at -78 °C. At -78 °C an aldehyde or a ketone is added and the reaction mixture is allowed to reach room temperature and kept at that temperature 15 for the appropriate time to form the alcohol I. Having isolated I, the mesylate J is formed in situ with methanesulfonyl chloride and triethyl amine, either at room temperature or with cooling. The reaction of the alcohol with this mesylate is either performed by adding the alcohol and a base such as triethyl amine to the mesylate in a solvent such as DCM or by pre-reacting the alcohol with a base such as sodium hydride in a solvent such as THF and subsequently adding the mesylate to this solution to form product (I).



SCHEME 2

Variations of compounds of formula I are investigated by first forming an aryl prop-2-ynyl ether M by reaction of a phenol K with 3-bromoprop-1-yne [= propargyl bromide] L in the presence of a base such as potassium carbonate in e.g. acetone at temperatures from room temperature to 60 °C for the appropriate time (Scheme 3). The propargyl ether M is then reacted in a Sonogashira coupling with an aryl bromide in the presence of a base such as triethyl amine at temperatures from room temperature to 60 °C for the appropriate time.



SCHEME 3

In the schemes 1, 2 and 3 above,  $R^1, R^2, R^3, R^4, R^5, R^6, Y^1, Y^2$  and  $Y^3$  are defined as for the compounds of formula I above.

5 *Experimental details*

DCM is dried over 3 $\text{\AA}$  molecular sieves. THF was distilled from Na/benzophenone just prior to use. All reactions are run under a nitrogen atmosphere. All glassware is dried in at 150 °C for at least two hours prior to its use. Phase separators from International Sorbent 10 Technology (IST) are used. Purification by chromatography is done either on silica gel 60 (0.040-0.063 mm), or by reverse phase chromatography with a C8 column. All NMR spectra are measured in  $\delta$ -chloroform.

2-bromo-6-methylpyridine is commercially available from Aldrich,  $(PPh_3)_2PdCl_2$  from Avacado,  $Pd(OAc)_2$  from Aldrich and  $CuI$  from Fluka. If not stated otherwise, the 15 chemicals used are commercially available and are used as such without further purification.

Pharmaceutical formulations

20 For clinical use, the compounds of formula I are in accordance with the present invention suitably formulated into pharmaceutical formulations for oral administration. Also rectal,

parenteral or any other route of administration may be contemplated to the skilled man in the art of formulations. Thus, the compounds of formula I are formulated with at least one pharmaceutically and pharmacologically acceptable carrier or adjuvant. The carrier may be in the form of a solid, semi-solid or liquid diluent.

5

In the preparation of oral pharmaceutical formulations in accordance with the invention, the compound of formula I to be formulated is mixed with solid, powdered ingredients such as lactose, saccharose, sorbitol, mannitol, starch, amylopectin, cellulose derivatives, gelatin, or another suitable ingredient, as well as with disintegrating agents and lubricating agents such as magnesium stearate, calcium stearate, sodium stearyl fumarate and polyethylene glycol waxes. The mixture is then processed into granules or compressed into tablets.

10

Soft gelatine capsules may be prepared with capsules containing a mixture of the active compound or compounds of the invention, vegetable oil, fat, or other suitable vehicle for soft gelatine capsules. Hard gelatine capsules may contain the active compound in combination with solid powdered ingredients such as lactose, saccharose, sorbitol, mannitol, potato starch, corn starch, amylopectin, cellulose derivatives or gelatine.

15

20 Dosage units for rectal administration may be prepared (i) in the form of suppositories which contain the active substance(s) mixed with a neutral fat base; (ii) in the form of a gelatine rectal capsule which contains the active substance in a mixture with a vegetable oil, paraffin oil, or other suitable vehicle for gelatine rectal capsules; (iii) in the form of a ready-made micro enema; or (iv) in the form of a dry micro enema formulation to be 25 reconstituted in a suitable solvent just prior to administration.

20

30 Liquid preparations for oral administration may be prepared in the form of syrups or suspensions, e.g. solutions or suspensions, containing the active compound and the remainder of the formulation consisting of sugar or sugar alcohols, and a mixture of ethanol, water, glycerol, propylene glycol and polyethylene glycol. If desired, such liquid

preparations may contain colouring agents, flavouring agents, saccharine and carboxymethyl cellulose or other thickening agent. Liquid preparations for oral administration may also be prepared in the form of a dry powder to be reconstituted with a suitable solvent prior to use.

5

Solutions for parenteral administration may be prepared as a solution of a compound of the invention in a pharmaceutically acceptable solvent. These solutions may also contain stabilizing ingredients and/or buffering ingredients and are dispensed into unit doses in the form of ampoules or vials. Solutions for parenteral administration may also be prepared as 10 a dry preparation to be reconstituted with a suitable solvent extemporaneously before use.


10

In one aspect of the present invention, the compounds of formula I may be administered once or twice daily, depending on the severity of the patient's condition.

15

A typical daily dose of the compounds of formula I is from 0.1 – 10 mg per kg body weight of the subject to be treated, but this will depend on various factors such as the route of administration, the age and weight of the patient as well as of severity of the patient's condition.

20

Examples*Method K*Example 15 Preparation of 3-(prop-2-yn-1-yloxy)benzene (compound 21):

Potassium carbonate (1.382 g, 0.1 mol) was added to a solution of phenol (0.941 g, 0.01 mmol, 1.0 eq.) in acetone (15 mL) at 0 °C. 3-bromoprop-1-yne (1.19 g, 0.89 mL, 0.01 mol, 1.0 eq.) was added. The solution was allowed to reach room temperature and then heated at 60 °C for 17h. After cooling, the solvent was evaporated.

Water (15 mL) was added and the mixture was extracted with EtOAc (3 x 15 mL). The combined organic phases were washed with water (1 x 15 mL), brine (1 x 15 mL), dried with magnesium sulphate and evaporated. This gave 1.026 g (78 %) of product.

15 TLC:  $R_f$  (heptane/EtOAc 2:1) = 0.67.

$^1\text{H}$  NMR (300 MHz): 7.32-7.24 (m, 2H), 7.02-6.92 (m, 3H), 4.64 (d,  $J$  = 2.4 Hz, 2H), 2.48 (t,  $J$  = 2.4 Hz, 1H).


$^{13}\text{C}$  NMR (75 MHz): 157.6, 129.8, 121.7, 115.1, 78.9, 75.7, 56.0.

20

Example 2

## Preparation of 1-methoxy-3-(prop-2-yn-1-yloxy)benzene (compound 22): according to method K above, with 3-methoxyphenol as starting material.

25




Yield: 99 %.

<sup>1</sup>H NMR (500 MHz): 7.20-7.14 (m 2H), 6.57-6.51 (m, 3H), 4.63 (d, *J* = 2.3 Hz, 2H), 3.74 (s, 3H), 2.51 (t, *J* = 2.4 Hz, 1H).

<sup>13</sup>C NMR (125 MHz): 160.8, 158.8, 129.9, 107.2, 106.9, 101.5, 78.6, 75.6, 55.8, 55.2.

5 Example 3

Preparation of 2-methyl-6-(3-phenoxyprop-1-yn-1-yl)pyridine (compound 23):



To 2-bromo-6-methylpyridine (1.055 g, 6.13 mmol) was added 3-(prop-2-yn-1-

10 yloxy)benzene (0.851 g, 6.44 mmol, 1.10 eq.), followed by (PPh<sub>3</sub>)<sub>2</sub>PdCl<sub>2</sub> (0.129 g, 0.18 mmol, 0.03 eq.), CuI (0.035 g, 0.18 mmol, 0.03 eq.) and triethylamine (3.50 mL). The mixture was heated under nitrogen at 60 °C for 2h. Phosphate buffer (10 mL, 0.2 M, pH 7), was added and the water phase was extracted with DCM (3 x 10 mL). The combined organic phases were dried with magnesium sulphate, evaporated and then filtered through a Si-plug, 1 g, while rinsing with diethyl ether/pentane 1:1, ca. 25 mL. This gave 1.491g after evaporation.


Flash chromatography on Si-gel with heptane/AcOEt, first 9:1, then 3:1, as eluent gave 0.908 g compound.

20 <sup>1</sup>H NMR (500 MHz): 7.42 (t, *J* = 7.8 Hz, 1H), 7.27 (t, *J* = 7.8, 2H), 7.17 (d, *J* = 7.7 Hz, 1H), 7.01 (m, 3H), 6.95 (t, *J* = 7.7 Hz, 1H), 4.88 (s, 2H), 2.94 (s, 3H).

<sup>13</sup>C NMR (125 MHz): 158.2, 157.1, 140.9, 135.8, 128.9, 123.7, 122.4, 120.8, 114.2, 85.8, 83.1, 55.7, 23.8.

25 Example 4

Preparation of 2-[3-(3-methoxyphenoxy)prop-1-yn-1-yl]-6-methylpyridine (compound 24):



To NaH (0.038 g, 95 % purity, 1.50 mmol, 5.0 eq.) in THF (1 mL) was added 1-methoxy-3-(prop-2-yn-1-yloxy)benzene (0.037 g, 0.30 mmol, 1.0 eq.) in THF (1 mL) at 0 °C under nitrogen. The mixture was stirred for 10 min. at room temperature. Then, 3-(6-methylpyridin-2-yl)prop-2-yn-1-yl methanesulfonate (0.068 g, 0.30 mmol) in THF (1 mL) was added at 0 °C. The mixture was stirred at room temperature over night (18 h). The mixture was poured onto water (10 mL) and the water phase was extracted with Et<sub>2</sub>O (2 x 10 mL) and then DCM (2 x 10 mL). The combined organic phases were dried with sodium sulphate and evaporated. This gave 0.041 g crude product which was then purified by reverse phase chromatography. This gave 0.009 g (yield: 12 %) product.


<sup>1</sup>H NMR (300 MHz): 7.52 (t, *J* = 7.8 Hz, 1H), 7.25 [m (under CDCl<sub>3</sub>-signal), 1H], 7.20 (t, *J* = 8.2 Hz, 1H), 7.10 (d, *J* = 7.8 Hz, 1H), 6.66-6.53 (m, 3H), 4.91 (s, 2H), 3.79 (s, 3H), 2.55 (s, 3H).

15

Example 5

Preparation of 2-[3-(3-methoxyphenoxy)prop-1-yn-1-yl]pyridine (compound 25): prepared according to example 3 with 2-bromopyridine and 1-methoxy-3-(prop-2-yn-1-yloxy)benzene as starting materials.

20



Biological evaluationFunctional assessment of mGluR5 antagonism in cell lines expressing mGluR5d

5 The properties of the compounds of the invention can be analyzed using standard assays for pharmacological activity. Examples of glutamate receptor assays are well known in the art as described in for example Aramori *et al.*, *Neuron* 8:757 (1992), Tanabe *et al.*, *Neuron* 8:169 (1992), Miller *et al.*, *J. Neuroscience* 15: 6103 (1995), Balazs, *et al.*, *J. Neurochemistry* 69:151 (1997). The methodology described in these publications is  
10 incorporated herein by reference. Conveniently, the compounds of the invention can be studied by means of an assay (FLIPR) that measures the mobilization of intracellular calcium,  $[Ca^{2+}]_i$  in cells expressing mGluR5 or another assay (IP3) that measures inositol phosphate turnover.

15 **FLIPR Assay**

Cells expressing human mGluR5d as described in WO97/05252 are seeded at a density of 100,000 cells per well on collagen coated clear bottom 96-well plates with black sides and experiments are done 24 h following seeding. All assays are done in a buffer containing 127 mM NaCl, 5 mM KCl, 2 mM MgCl<sub>2</sub>, 0.7 mM NaH<sub>2</sub>PO<sub>4</sub>, 2 mM CaCl<sub>2</sub>, 0.422 mg/ml 20 NaHCO<sub>3</sub>, 2.4 mg/ml HEPES, 1.8 mg/ml glucose and 1 mg/ml BSA Fraction IV (pH 7.4). Cell cultures in the 96-well plates are loaded for 60 minutes in the above mentioned buffer containing 4  $\mu$ M of the acetoxymethyl ester form of the fluorescent calcium indicator fluo-3 (Molecular Probes, Eugene, Oregon) in 0.01% pluronic acid (a proprietary, non-ionic surfactant polyol - CAS Number 9003-11-6). Following the loading period the fluo-3 25 buffer is removed and replaced with fresh assay buffer. FLIPR experiments are done using a laser setting of 0.800 W and a 0.4 second CCD camera shutter speed with excitation and emission wavelengths of 488 nm and 562 nm, respectively. Each experiment is initiated with 160  $\mu$ l of buffer present in each well of the cell plate. A 40  $\mu$ l addition from the antagonist plate was followed by a 50  $\mu$ L addition from the agonist plate. A 90 second 30 interval separates the antagonist and agonist additions. The fluorescence signal is sampled 50 times at 1 second intervals followed by 3 samples at 5 second intervals immediately after each of the two additions. Responses are measured as the difference between the peak

height of the response to agonist, less the background fluorescence within the sample period. IC<sub>50</sub> determinations are made using a linear least squares fitting program.

5 *IP3 Assay*

An additional functional assay for mGluR5d is described in WO97/05252 and is based on phosphatidylinositol turnover. Receptor activation stimulates phospholipase C activity and leads to increased formation of inositol 1,4,5,triposphate (IP<sub>3</sub>).

GHEK stably expressing the human mGluR5d are seeded onto 24 well poly-L-lysine 10 coated plates at 40 x 10<sup>4</sup> cells /well in media containing 1  $\mu$ Ci/well [3H] myo-inositol. Cells were incubated overnight (16 h), then washed three times and incubated for 1 h at 37°C in HEPES buffered saline (146 mM NaCl, 4.2 mM KCl, 0.5 mM MgCl<sub>2</sub>, 0.1% 15 glucose, 20 mM HEPES, pH 7.4) supplemented with 1 unit/ml glutamate pyruvate transaminase and 2 mM pyruvate. Cells are washed once in HEPES buffered saline and 20 pre-incubated for 10 min in HEPES buffered saline containing 10 mM LiCl. Compounds are incubated in duplicate at 37°C for 15 min, then either glutamate (80  $\mu$ M) or DHPG (30  $\mu$ M) is added and incubated for an additional 30 min. The reaction is terminated by the 25 addition of 0.5 ml perchloric acid (5%) on ice, with incubation at 4°C for at least 30 min. Samples are collected in 15 ml polypropylene tubes and inositol phosphates are separated using ion-exchange resin (Dowex AG1-X8 formate form, 200-400 mesh, BIORAD) columns. Inositol phosphate separation was done by first eluting glycero phosphatidyl inositol with 8 ml 30 mM ammonium formate. Next, total inositol phosphates is eluted with 8 ml 700 mM ammonium formate / 100 mM formic acid and collected in scintillation vials. This eluate is then mixed with 8 ml of scintillant and [3H] inositol incorporation is determined by scintillation counting. The dpm counts from the duplicate samples are plotted and IC<sub>50</sub> determinations are generated using a linear least squares fitting program.

*Abbreviations*

30	BSA	Bovine Serum Albumin
	CCD	Charge Coupled Device

CRC	Concentration Response Curve
DHPG	3,5-dihydroxyphenylglycine
DPM	Disintegrations per Minute
EDTA	Ethylene Diamine Tetraacetic Acid
FLIPR	Fluorometric Imaging Plate reader
GHEK	GLAST-containing Human Embryonic Kidney
GLAST	glutamate/aspartate transporter
HEPES	4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (buffer)
IP <sub>3</sub>	inositol triphosphate

10

Generally, the compounds are active in the assay above with IC<sub>50</sub> values less than 10 000 nM. In one aspect of the invention, the IC<sub>50</sub> value is less than 1  $\mu$ M. In a further aspect of the invention, the IC<sub>50</sub> value is less than 100 nM.

15

*Screening for compounds active against TLESR*

20

Adult Labrador retrievers of both genders, trained to stand in a Pavlov sling, are used. Mucosa-to-skin esophagostomies are formed and the dogs are allowed to recover completely before any experiments are done.

*Motility measurement*

25


In brief, after fasting for approximately 17 h with free supply of water, a multilumen sleeve/sidehole assembly (Dentsleeve, Adelaide, South Australia) is introduced through the esophagostomy to measure gastric, lower esophageal sphincter (LES) and esophageal pressures. The assembly is perfused with water using a low-compliance manometric perfusion pump (Dentsleeve, Adelaide, South Australia). An air-perfused tube is passed in the oral direction to measure swallows, and an antimony electrode monitored pH, 3 cm above the LES. All signals are amplified and acquired on a personal computer at 10 Hz.

When a baseline measurement free from fasting gastric/LES phase III motor activity has been obtained, placebo (0.9% NaCl) or test compound is administered intravenously (i.v., 0.5 ml/kg) in a foreleg vein. Ten min after i.v. administration, a nutrient meal (10% peptone, 5% D-glucose, 5% Intralipid, pH 3.0) is infused into the stomach through the 5 central lumen of the assembly at 100 ml/min to a final volume of 30 ml/kg. The infusion of the nutrient meal is followed by air infusion at a rate of 500 ml/min until an intragastric pressure of  $10\pm1$  mmHg is obtained. The pressure is then maintained at this level throughout the experiment using the infusion pump for further air infusion or for venting air from the stomach. The experimental time from start of nutrient infusion to end of air 10 insufflation is 45 min. The procedure has been validated as a reliable means of triggering TLESRs.

TLESRs is defined as a decrease in lower esophageal sphincter pressure (with reference to intragastric pressure) at a rate of  $>1$  mmHg/s. The relaxation should not be preceded by a 15 pharyngeal signal  $\leq 2$ s before its onset in which case the relaxation is classified as swallow-induced. The pressure difference between the LES and the stomach should be less than 2 mmHg, and the duration of the complete relaxation longer than 1 s.

Claims

## 1. A compound of formula I



5

wherein

R<sup>1</sup> is selected from hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, aryl and heteroaryl, wherein the aryl or heteroaryl may be substituted by C<sub>1</sub>-C<sub>4</sub> alkyl;

10

R<sup>2</sup> is selected from hydrogen and C<sub>1</sub>-C<sub>4</sub> alkyl;

R<sup>3</sup> is selected from hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, F, CF<sub>3</sub>, CHF<sub>2</sub> and CH<sub>2</sub>F;

R<sup>4</sup> is selected from hydrogen, F, CF<sub>3</sub>, CHF<sub>2</sub>, CH<sub>2</sub>F and CH<sub>3</sub>;

R<sup>5</sup> is selected from hydrogen and F;

R<sup>6</sup> is selected from hydrogen and F;

15

Y<sup>1</sup> is selected from hydrogen, halogen, nitrile, C<sub>1</sub>-C<sub>4</sub> alkoxy, and C<sub>1</sub>-C<sub>4</sub> alkyl;

Y<sup>2</sup> is selected from hydrogen, halogen, nitrile, C<sub>1</sub>-C<sub>4</sub> alkoxy, and C<sub>1</sub>-C<sub>4</sub> alkyl;

Y<sup>3</sup> is selected from hydrogen, halogen, nitrile, C<sub>1</sub>-C<sub>4</sub> alkoxy, and C<sub>1</sub>-C<sub>4</sub> alkyl;

20

with the proviso that when Y<sup>1</sup> is hydrogen, Y<sup>2</sup> is selected from halogen, nitrile, C<sub>1</sub>-C<sub>4</sub> alkoxy, and C<sub>1</sub>-C<sub>4</sub> alkyl;

25

as well as pharmaceutically acceptable salts, hydrates, isoforms and/or optical isomers thereof.

## 2. A compound according to formula I of claim 1, wherein

R<sup>1</sup> is hydrogen or C<sub>1</sub>-C<sub>3</sub> alkyl;

25

R<sup>2</sup> is hydrogen;

R<sup>3</sup> is selected from hydrogen and C<sub>1</sub>-C<sub>2</sub> alkyl;

R<sup>4</sup> is hydrogen;

R<sup>5</sup> is hydrogen;

R<sup>6</sup> is hydrogen;

5 Y<sup>1</sup> is selected from hydrogen, chloro, C<sub>1</sub>-C<sub>2</sub> alkoxy, and C<sub>1</sub>-C<sub>2</sub> alkyl; and

Y<sup>2</sup> is selected from hydrogen, chloro, C<sub>1</sub>-C<sub>2</sub> alkoxy, and C<sub>1</sub>-C<sub>2</sub> alkyl;

with the proviso that when Y<sup>1</sup> is hydrogen, Y<sup>2</sup> is selected from chloro, C<sub>1</sub>-C<sub>2</sub> alkoxy, and C<sub>1</sub>-C<sub>2</sub> alkyl; and

Y<sup>3</sup> is hydrogen.

10

3. A compound according to claim 1 selected from 2-methyl-6-(3-phenoxyprop-1-yn-1-yl)pyridine, 2-[3-(3-methoxyphenoxy)prop-1-yn-1-yl]pyridine and 2-[3-(3-methoxyphenoxy)prop-1-yn-1-yl]pyridine.

15

4. A compound according to any one of claims 1-3 for use in therapy.

5. A compound according to claim 4, wherein the therapy is treatment or prevention of gastroesophageal reflux disease.

20

6. Use of a compound according to formula I of claim 1, or a pharmaceutically acceptable salt or an optical isomer thereof, for the manufacture of a medicament for the inhibition of transient lower esophageal sphincter relaxations.


25

7. Use of a compound according to formula I of claim 1, or a pharmaceutically acceptable salt or an optical isomer thereof, for the manufacture of a medicament for treatment or prevention of gastroesophageal reflux disease.


30

8. A pharmaceutical composition comprising a compound of formula I as an active ingredient, together with a pharmacologically and pharmaceutically acceptable carrier.


9. A process for the preparation of a compound of formula I, whereby a coupling reaction of the aryl bromide A



5 and the alcohol B




is performed in the presence of a base such as triethyl amine to give the alcohol C



10

which is then converted into the mesylate D



15

and reacted with an alcohol, and wherein

R1 is selected from hydrogen, C1-C4 alkyl, C3-C6 cycloalkyl, aryl and heteroaryl, wherein the aryl or heteroaryl may be substituted by C1-C4 alkyl;

R2 is selected from hydrogen and C1-C4 alkyl;

$R^3$  is selected from hydrogen,  $C_1$ - $C_4$  alkyl, F,  $CF_3$ ,  $CHF_2$  and  $CH_2F$ ;

$R^4$  is selected from hydrogen, F,  $CF_3$ ,  $CHF_2$ ,  $CH_2F$  and  $CH_3$ ;

$R^5$  is selected from hydrogen and F;

$R^6$  is selected from hydrogen and F.


5

- 10 10. A method for the inhibition of transient lower esophageal sphincter relaxations whereby an effective amount of a compound of formula I is administered to a subject in need of such inhibition.
11. A method for the treatment or prevention of gastroesophageal reflux disease, whereby an effective amount of a compound of formula I is administered to a subject in need of such treatment or prevention.

Abstract

The present invention is directed to novel compounds of formula I, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds.

5



wherein

R<sup>1</sup> is selected from hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, aryl and heteroaryl, wherein the aryl or heteroaryl may be substituted by C<sub>1</sub>-C<sub>4</sub> alkyl;

10 R<sup>2</sup> is selected from hydrogen and C<sub>1</sub>-C<sub>4</sub> alkyl;

R<sup>3</sup> is selected from hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, F, CF<sub>3</sub>, CHF<sub>2</sub> and CH<sub>2</sub>F;

R<sup>4</sup> is selected from hydrogen, F, CF<sub>3</sub>, CHF<sub>2</sub>, CH<sub>2</sub>F and CH<sub>3</sub>;

R<sup>5</sup> is selected from hydrogen and F;

15 R<sup>6</sup> is selected from hydrogen and F;

Y<sup>1</sup> is selected from hydrogen, halogen, nitrile, C<sub>1</sub>-C<sub>4</sub> alkoxy, and C<sub>1</sub>-C<sub>4</sub> alkyl;

Y<sup>2</sup> is selected from hydrogen, halogen, nitrile, C<sub>1</sub>-C<sub>4</sub> alkoxy, and C<sub>1</sub>-C<sub>4</sub> alkyl;

Y<sup>3</sup> is selected from hydrogen, halogen, nitrile, C<sub>1</sub>-C<sub>4</sub> alkoxy, and C<sub>1</sub>-C<sub>4</sub> alkyl; with the proviso that when Y<sup>1</sup> is hydrogen, Y<sup>2</sup> is selected from halogen, nitrile, C<sub>1</sub>-C<sub>4</sub> alkoxy, and C<sub>1</sub>-C<sub>4</sub> alkyl;

20 as well as pharmaceutically acceptable salts, hydrates, isoforms and/or optical isomers thereof.

### Application Data Sheet

#### **Application Information**

**Application Type::** Regular  
**Subject Matter::** Utility  
**Suggested classification::**  
**Suggested Group Art Unit::**  
**CD-ROM or CD-R?::** None  
**Computer Readable Form (CRF)?::** No  
**Title::** NOVEL COMPOUNDS III  
**Attorney Docket Number::** 085747-0304  
**Request for Early Publication?::** No  
**Request for Non-Publication?::** No  
**Suggested Drawing Figure::**  
**Total Drawing Sheets::**  
**Small Entity?::** No  
**Petition Included?::** No  
**Secrecy Order in Parent Appl.?::** No

#### **Applicant Information**

**Applicant Authority Type::** Inventor  
**Primary Citizenship Country::** US  
**Status::** Full Capacity  
**Given Name::** Peter  
**Family Name::** BACH  
**City of Residence::** Molndal  
**Country of Residence::** Sweden  
**Street of mailing address::** AstraZeneca R&D Molndal  
83 Molndal  
SE-431  
**Country of mailing address::** Sweden  
  
**Applicant Authority Type::** Inventor  
**Primary Citizenship Country::** US  
**Status::** Full Capacity

**Given Name::** Udo  
**Family Name::** BAUER  
**City of Residence::** Molndal  
**Country of Residence::** Sweden  
**Street of mailing address::** AstraZeneca R&D Molndal  
83 Molndal  
SE-431  
**Country of mailing address::** Sweden

**Applicant Authority Type::** Inventor  
**Primary Citizenship Country::** US  
**Status::** Full Capacity  
**Given Name::** Karolina  
**Family Name::** NILSSON  
**City of Residence::** Molndal  
**Country of Residence::** Sweden  
**Street of mailing address::** AstraZeneca R&D Molndal  
83 Molndal  
SE-431  
**Country of mailing address::** Sweden

**Applicant Authority Type::** Inventor  
**Primary Citizenship Country::** US  
**Status::** Full Capacity  
**Given Name::** Andreas  
**Family Name::** WALLBERG  
**City of Residence::** Molndal  
**Country of Residence::** Sweden  
**Street of mailing address::** AstraZeneca R&D Molndal  
83 Molndal  
SE-431  
**Country of mailing address::** Sweden

**Correspondence Information**

**Correspondence Customer Number::** 22428  
**E-Mail address::** PTOMailWashington@Foley.com

**Representative Information**

<b>Representative Customer Number::</b>	22428	
---	-------	--

**Domestic Priority Information**

<b>Application::</b>	<b>Continuity Type::</b>	<b>Parent Application::</b>	<b>Parent Filing Date::</b>

**Foreign Priority Information**

<b>Country::</b>	<b>Application number::</b>	<b>Filing Date::</b>	<b>Priority Claimed::</b>

**Assignee Information****Assignee name::**

AstraZeneca and NPS Pharmaceuticals, Inc.

From the INTERNATIONAL BUREAU

## PCT

NOTIFICATION CONCERNING  
SUBMISSION OR TRANSMITTAL  
OF PRIORITY DOCUMENT

(PCT Administrative Instructions, Section 411)

To:

BENT, Stephen, A.  
Foley & Lardner LLP  
Washington Harbour  
3000 K Street, NW, Suite 500  
Washington, D.C. 20007-5101  
ETATS-UNIS D'AMERIQUE

Date of mailing (day/month/year) 16 December 2004 (16.12.2004)	
Applicant's or agent's file reference ALKYNES III	<b>IMPORTANT NOTIFICATION</b>
International application No. PCT/US04/034501	International filing date (day/month/year) 20 October 2004 (20.10.2004)
International publication date (day/month/year)	Priority date (day/month/year) 31 October 2003 (31.10.2003)
Applicant	ASTRAZENECA AB et al

1. By means of this Form, which replaces any previously issued notification concerning submission or transmittal of priority documents, the applicant is hereby notified of the date of receipt by the International Bureau of the priority document(s) relating to all earlier application(s) whose priority is claimed. Unless otherwise indicated by the letters "NR", in the right-hand column or by an asterisk appearing next to a date of receipt, the priority document concerned was submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b).
2. *(If applicable)* The letters "NR" appearing in the right-hand column denote a priority document which, on the date of mailing of this Form, had not yet been received by the International Bureau under Rule 17.1(a) or (b). Where, under Rule 17.1(a), the priority document must be submitted by the applicant to the receiving Office or the International Bureau, but the applicant fails to submit the priority document within the applicable time limit under that Rule, the attention of the applicant is directed to Rule 17.1(c) which provides that no designated Office may disregard the priority claim concerned before giving the applicant an opportunity, upon entry into the national phase, to furnish the priority document within a time limit which is reasonable under the circumstances.
3. *(If applicable)* An asterisk (\*) appearing next to a date of receipt, in the right-hand column, denotes a priority document submitted or transmitted to the International Bureau but not in compliance with Rule 17.1(a) or (b) (the priority document was received after the time limit prescribed in Rule 17.1(a) or the request to prepare and transmit the priority document was submitted to the receiving Office after the applicable time limit under Rule 17.1(b)). Even though the priority document was not furnished in compliance with Rule 17.1(a) or (b), the International Bureau will nevertheless transmit a copy of the document to the designated Offices, for their consideration. In case such a copy is not accepted by the designated Office as the priority document, Rule 17.1(c) provides that no designated Office may disregard the priority claim concerned before giving the applicant an opportunity, upon entry into the national phase, to furnish the priority document within a time limit which is reasonable under the circumstances.

<u>Priority date</u>	<u>Priority application No.</u>	<u>Country or regional Office or PCT receiving Office</u>	<u>Date of receipt of priority document</u>
31 October 2003 (31.10.2003)	60/560,754	US	06 December 2004 (06.12.2004)

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland  Facsimile No. +41 22 740 14 35	Authorized officer  Giffo Schmitt Beate  Facsimile No. +41 22 338 87 20 Telephone No. +41 22 338 9241
---	--